A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Qualified researchers may request access to individual patient-level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (http://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/data). For up-to-date information on the study, visit ppmi-info.org.
Subject Area
- Addiction Medicine (331)
- Allergy and Immunology (657)
- Anesthesia (175)
- Cardiovascular Medicine (2555)
- Dermatology (216)
- Emergency Medicine (388)
- Epidemiology (12052)
- Forensic Medicine (10)
- Gastroenterology (736)
- Genetic and Genomic Medicine (3964)
- Geriatric Medicine (373)
- Health Economics (661)
- Health Informatics (2557)
- Health Policy (989)
- Hematology (356)
- HIV/AIDS (820)
- Medical Education (392)
- Medical Ethics (106)
- Nephrology (420)
- Neurology (3731)
- Nursing (205)
- Nutrition (557)
- Oncology (1939)
- Ophthalmology (565)
- Orthopedics (233)
- Otolaryngology (299)
- Pain Medicine (245)
- Palliative Medicine (72)
- Pathology (469)
- Pediatrics (1086)
- Primary Care Research (442)
- Public and Global Health (6396)
- Radiology and Imaging (1352)
- Respiratory Medicine (854)
- Rheumatology (390)
- Sports Medicine (336)
- Surgery (429)
- Toxicology (51)
- Transplantation (184)
- Urology (161)